Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Pharmacokinetics|October 9, 2008
Regulatory aspects of pharmacokinetic profiling in special populations: a European perspectiveMonica Edholm, Eva Gil Berglund, Tomas Salmonson
Clinical Pharmacology and Therapeutics|April 30, 2024
Dose Optimization Informed by PBPK Modeling: State-of-the Art and FutureKaren Rowland Yeo, Eva Gil Berglund, Yuan Chen
Clinical Chemistry and Laboratory Medicine|October 29, 2003
CYP3A4 and MDR1 alleles in a Portuguese populationIsa Cavaco, J Pedro Gil, Eva Gil-Berglund, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 21, 2021
A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug developmentTrevor N Johnson, Ben G Small, Eva Gil Berglund, et al.
Journal of Clinical Pharmacology|March 21, 2020
Inhibitors of Organic Anion-Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory PerspectiveSavannah J McFeely, Tasha K Ritchie, Jingjing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2012
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Sigrid Klaar, Eva Gil Berglund, et al.
Clinical Pharmacokinetics|November 12, 2013
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsVicky Hsu, Manuela de L T Vieira, Ping Zhao, et al.
Frontiers in Pharmacology|July 7, 2020
Artificial Intelligence and Machine Learning Applied at the Point of CareZuzanna Angehrn, Liina Haldna, Anthe S Zandvliet, et al.
Biopharmaceutics & Drug Disposition|January 25, 2012
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practiceJoseph A Grillo, Ping Zhao, Julie Bullock, et al.
The AAPS Journal|June 2, 2011
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical developmentSandhya Girish, Steven W Martin, Mark C Peterson, et al.
Pageof 2